Monte Rosa Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Monte Rosa Therapeutics, Inc. (GLUE) reported Increase (Decrease) in Deferred Revenue of -$13.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$8.97M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$4.21M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $4.22M, a 95.28% decline year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $110.22M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was $7.52M, a 90.98% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $83.38M, a 66.76% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $50.00M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$13.18M 10-Q · filed 2026-08-06 | -$8.96M derived: sum of 3 quarters · filed 2026-08-06 | $101.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.21M 10-Q · filed 2026-05-07 | $9.00K derived: sum of 2 quarters · filed 2026-05-07 | $110.22M derived: sum of 3 quarters · filed 2026-05-07 | $87.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $114.43M derived: sum of 2 quarters · filed 2026-03-17 | $91.46M derived: sum of 3 quarters · filed 2026-08-06 | $7.52M 10-K · filed 2026-03-17 |
| 2025-09-30 | $110.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $87.25M derived: sum of 2 quarters · filed 2026-08-06 | $3.31M 10-Q · filed 2025-11-06 | $92.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$22.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$106.91M 10-Q · filed 2026-08-06 | -$17.56M derived: sum of 3 quarters · filed 2026-08-06 | -$26.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$83.94M 10-Q · filed 2026-05-07 | $5.41M derived: sum of 2 quarters · filed 2026-05-07 | -$3.80M derived: sum of 3 quarters · filed 2026-05-07 | $502.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $89.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $80.14M derived: sum of 2 quarters · filed 2026-03-17 | $84.44M derived: sum of 3 quarters · filed 2026-03-17 | $83.38M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$9.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.91M derived: sum of 2 quarters · filed 2025-11-06 | -$5.97M 10-Q · filed 2025-11-06 | $44.02M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.24M 10-Q · filed 2025-08-07 | $53.24M derived: sum of 3 quarters · filed 2025-08-07 | $53.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.06M 10-Q · filed 2025-05-08 | $48.94M derived: sum of 2 quarters · filed 2025-05-08 | $48.94M derived: sum of 3 quarters · filed 2025-05-08 | $48.94M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $50.00M derived: sum of 2 quarters · filed 2025-03-20 | $50.00M derived: sum of 3 quarters · filed 2025-03-20 | $50.00M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |